Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | FDA approval of valbenazine & unanswered questions in Huntington’s disease

Erin Furr Stimming, MD, FAAN, FANA, McGovern Medical School, UTHealth, Houston, TX, highlights the impact valbenazine’s approval can have on individuals living with Huntington’s disease and those at risk. With Huntington’s disease often remaining in the shadows due to its rarity, raising awareness and educating the public and healthcare providers about it is crucial. The approval of valbenazine for adults with Huntington’s disease-related chorea is a positive step, but there is still work to be done, particularly in disease modification. Currently, no approved medications slow or halt disease progression, although efforts are underway to modify the gene or huntingtin. While progress is being made, it is essential to effectively treat the symptoms of HD, including non-motor symptoms such as cognitive impairment. Ongoing clinical trials are evaluating the efficacy and safety of medications for cognitive symptoms. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.